Le Lézard
Classified in: Health, Science and technology

DiviTum(R) TKa Clinical Validation Data Published in Biomarkers

UPPSALA, SE / ACCESSWIRE / January 31, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces that results clinically validating the DiviTum® TKa assay have been published in the scientific journal Biomarkers. The results, from an analysis of samples and clinical data from the SWOG S0226 study, support the use of DiviTum® TKa when monitoring metastatic breast cancer patients and were the foundation leading to FDA clearance of the assay.

"The analysis of samples and data from SWOG S0226, provided the clinical validation data that resulted in 510(k) clearance of DivTum® TKa from the FDA. The fact that this work now has also been accepted and published in a scientific journal enables Biovica to use these strong data as an asset when promoting DiviTum® TKa to customers. DiviTum® TKa is a tool for effective monitoring of treatments within metastatic breast cancer, something that will benefit both patients and health care providers," said Anders Rylander, CEO of Biovica.

Among the patient samples tested, DiviTum® TKa test values below the pre-specified cut-off, both before and during treatment, predicted low likelihood of disease progression - the so-called Negative Predictive Value (NPV) - with very high accuracy and precision. The DiviTum® TKa test's NPVs for disease progression within 30 and 60 days after TKa testing were 96.7% and 93.5%, respectively. This means that 96.7% of patients with DiviTum® TKa measurements below the assay clinical cut-off did not experience disease progression within the next 30 days. A high NPV reveals that it is unlikely for a woman to progress in the disease, indicating that the current treatment is effective.

Further, a low TKa value at first follow up (approx. 8 weeks into treatment) indicated longer time to progression vs. high TKa values; 17.5 vs 7.7 months with corresponding numbers for overall survival being 56.6 vs 27.4 months.

Investigators conclude that low serum DiviTum® TKa levels can identify patients who will do well for a long time as well as patients who might forego additional therapy added to standard, single-agent endocrine therapy. The combined effect of avoiding ancillary treatments with a possible reduction of inconvenient and costly serial imaging, should improve the quality of life for patients.

Link to study: https://www.tandfonline.com/doi/full/10.1080/1354750X.2023.2168063


Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: [email protected]

Biovica - Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com


DiviTum® TKa clinical validation data published in Biomarkers

SOURCE: Biovica International

View source version on accesswire.com:

These press releases may also interest you

at 01:00
CodeSteri, a leading provider of disinfection solutions, is proud to announce the launch of PlaClin-M, a revolutionary device designed to help ensure a clean and safe environment in offices, commercial establishments, and public spaces. CodeSteri...

at 00:01
As infectious disease outbreaks and extreme weather events threaten the health of more Americans, a new report shows the need for strengthened national and state public health emergency preparedness....

22 mar 2023
DURACORE, a manufacturer of high-performance active living products, has entered into an exclusive partnership with Five at Heart, a leading provider of bike room, change room, and modern office solutions based in Brisbane, Australia. The partnership...

22 mar 2023
Ionis today announced the outcome of the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with...

22 mar 2023
The "Research Antibodies and Reagents Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the...

22 mar 2023
The "Healthcare E-Commerce Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The...

News published on 31 january 2023 at 03:20 and distributed by: